{"document_type": "article", "snippet": "Martin Shkreli drew criticism for raising the price of the drug Daraprim to $750 a pill from $13.50, but the move suggests he has enough chutzpah to be president.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/11/business/mutfund/take-surge-pricing-to-the-limit-then-go-further.html", "subsection_name": "Mutual Funds", "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-11T00:00:00Z", "word_count": "1037", "slideshow_credits": null, "news_desk": "SundayBusiness", "byline": {"original": "By JOHN SCHWARTZ", "person": [{"role": "reported", "lastname": "SCHWARTZ", "rank": 1, "organization": "", "firstname": "John"}]}, "abstract": "John Schwartz essay humorously observes Turing Pharmaceuticals founder Martin Shkreli, who bought drug Daraprim and jacked its price to $750 a pill, from $13.50, is using variant on surge pricing; says it shows 32-year-old has chutzpah to go to the top, and asks him to run for president when he turns 35.", "keywords": [{"value": "Drugs (Pharmaceuticals)", "rank": "1", "name": "subject", "is_major": "Y"}, {"value": "Shkreli, Martin (1983- )", "rank": "2", "name": "persons", "is_major": "Y"}, {"value": "Turing Pharmaceuticals AG", "rank": "3", "name": "organizations", "is_major": "Y"}, {"value": "Presidential Election of 2016", "rank": "4", "name": "subject", "is_major": "N"}], "print_page": "12", "multimedia": [], "lead_paragraph": "Martin Shkreli drew criticism for raising the price of the drug Daraprim to $750 a pill from $13.50, but the move suggests he has enough chutzpah to be president.", "headline": {"kicker": "Essay", "content_kicker": "Essay", "print_headline": "Take Prices to the Limit. Then Keep Going.", "main": "Take Surge Pricing to the Limit. Then Go Further."}, "_id": "5617fa2638f0d814e137028a"}